Kawasaki disease

Vascular Medicine

Volumn 4, Issue 3, 1999, Pages 187-202

  Newburger, Jane W ^a   Burns, Jane C ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Acquired heart disease; Coronary artery aneurysms; Kawasaki disease; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CORTICOSTEROID; FIBRINOLYTIC AGENT; IMMUNOGLOBULIN; PENTOXIFYLLINE;

AGE DISTRIBUTION; ANGIOCARDIOGRAPHY; CORONARY ARTERY ANEURYSM; HEART CATHETERIZATION; HUMAN; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOSIS;

EID: 0032836979     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358836x9900400310     Document Type: Review

References (185)

1. Kawasaki T. Acute febrile mucocutaneous lymph node syndrome: clinical observations of 50 cases. Jpn J Allergology 1967; 16: 178-222.
2. Yamamoto T, Kimura J. Carditis complicating a case of acute febrile mucocutaneous lymph node syndrome (Kawasaki): a subtype of mucocutaneous ocular syndrome or erythema multiforme. Shonika Rinsho 1968; 21: 236-39.
3. Kato H, Ichinose E, Yoshioka F et al. Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol 1982; 49: 1758-66.
4. Kato H, Ichinose E, Kawasaki T. Myocardial infarction in Kawasaki disease: clinical analyses in 195 cases. J Pediatr 1986; 108: 923-27.
5. Suzuki A, Kamiya T, Kuwahara N et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr Cardiol 1986; 7: 3-9.
6. Taubert KA, Rowley AH, Shulman ST. Seven-year national survey of Kawasaki disease and acute rheumatic fever. Pediatr Infect Dis J 1994; 13: 704-708.
7. Landing BH, Larson EJ. Are infantile periarteritis with coronary artery involvement and fatal mucocutaneous lymph node syndrome the same? Comparison of 20 patients from Hawaii and Japan. Pediatrics 1977; 59: 651-62.
8. Gee SJ. Cases of morbid anatomy: aneurysms of coronary arteries in a boy. St Bartholomew's Hospital Reports 7: 1871
9. Lie JT. Infantile polyarteritis and fatal cases of Kawasaki syndrome: diseases or one? Prog Clin Biol Res 1987; 250: 521-52.
10. Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Results of 12 nationwide epidemiological incidence surveys of Kawasaki disease in Japan. Arch Pediatr Adolesc Med 1995; 149: 779-83.
11. Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. Pediatrics 1995; 95: 475-79.
12. Melish ME, Hicks RM, Larson EJ. Mucocutaneous lymph node syndrome in the United States. Am J Dis Child 1976; 130: 599-607.
13. Davis RL, Waller PL, Mueller BA, Dykewicz CA, Schonberger LB. Kawasaki syndrome in Washington State. Race-specific incidence rates and residential proximity to water. Arch Pediatr Adolesc Med 1995; 149: 66-69.
14. Bronstein DE. Passive surveillance for Kawasaki disease in San Diego County. Pediatr Infect Dis J 1997; 16: 1015-18.
15. Momenah T, Sanatani S, Potts J, Sandor GG, Human DG, Patterson MW. Kawasaki disease in the older child. Pediatrics 1998; 102 (1): e7.
16. Fujita Y, Nakamura Y, Sakata K et al. Kawasaki disease in families. Pediatrics 1989; 84: 666-69.
17. Harada F, Sada M, Kamiya T, Yanase Y, Kawasaki T. Genetic analysis of Kawasaki syndrome. Am J Hum Genet 1986; 39: 537-39.
18. Bruckheimer E, Bulbul Z, McCarthy P, Madri JA, Friedman AH, Hellenbrand WE. Kawasaki disease: coronary aneurysms in mother and son. Circulation 1998; 97: 410-11.
19. Yanagawa H, Yashiro M, Nakamura Y, Hirose K, Kawasaki T. Nationwide surveillance of Kawasaki Disease in Japan, 1984-1993. Pediatr Infect Dis J 1995; 14: 69-71.
20. Rauch AM. Kawasaki syndrome: review of new epidemiologic and laboratory developments. Pediatr Infect Dis J 1987; 6: 1016-21.
21. Daniels SR, Specker B. Association of rug shampooing and Kawasaki disease. J Pediatr 1991; 118: 485-88.
22. Konishi N, Baba K, Abe J et al. A case of Kawasaki disease with coronary artery aneurysms documenting Yersinia pseudotuberculosis infection. Acta Paediatr 1997; 86: 661-64.
23. Rowley AH, Wolinsky SM, Relman DA et al. Search for highly conserved viral and bacterial nucleic acid sequences corresponding to an etiologic agent of Kawasaki Disease. Pediatr Res 1994; 36(5): 567-71.
24. Abe J, Kotzin BL, Jujo K et al. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci USA 1992; 89: 4066-70.
25. Yamashiro Y, Nagata S, Oguchi S, Shimizu T. Selective increase of VB2+ T cells in the small intestinal mucosa in Kawasaki Disease. Pediatr Res 1996; 39: 264-66.
26. Leung DYM, Giorno RC, Kazemi LV, Flynn PA, Busse JB. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol 1995; 155: 5018-21.
27. Leung DYM. Superantigens related to Kawasaki syndrome. Springer Semin Immunopathol 1996; 17: 385-96.
28. Pietra BA, De IJ, Giannini EH, Hirsch R. TCR V beta family repertoire and T cell activation markers in Kawasaki disease. J Immunol 1994; 153: 1881-88.
29. Choi IH, Chwae YJ, Shim WS et al. Clonal expression of CD8+ T cells in Kawasaki Disease. J Immunol 1997; 159: 481-86.
30. Jason J, Montana E, Donald F, Seidman M, Inge KL, Campbell R. Kawasaki disease and the T-cell antigen receptor. Hum Immunol 1998; 59: 29-38.
31. De Inocencio J, Hirsch R. The role of T cells in Kawasaki disease. Crit Rev Immimol 1995; 15 (3&4): 349-57.
32. Rowley AH, Eckerley CA, Jack HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J Immimol 1997; 159 (12): 5946-55.
33. Furukawa S, Matsubara T, Yabuta K. Mononuclear cell subsets and coronary artery lesions in Kawasaki disease. Arch Dis Child 1992; 67: 706-708.
34. Furukawa S, Matsubara T, Motohashi T, Nakachi S, Sasai K, Yabuta K. Expression of Fc epsilon R2/CD23 on peripheral blood macrophages/monocytes in Kawasaki disease. Clin Immunol Immunopathol 1990; 56: 280-86.
35. Leung DYM, Siefel RL, Grady S et al. Immunoregulatory abnormalities in MCLNS. Clin Immunol Immunopathol 1982; 23: 100-12.
36. Leung DY, Collins T, Lapierre LA, Geha RS, Pober JS. Immunoglobulin M antibodies present in the acute phase of Kawasaki syndrome lyse cultured vascular endothelial cells stimulated by gamma interferon. J Clin Invest 1986; 77: 1428-35.
37. Leung DY, Geha RS, Newburger JW et al. Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome. J Exp Med 1986; 164: 1958-72.
38. Suzuki H, Uemura S, Tone S et al. Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1-beta by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur J Pediatr 1996; 155: 291-96.
39. Fujieda M, Oishi N, Kurashige T. Antibodies to endothelial cells in Kawasaki disease lyse endothelial cells without cytokinc pretreatment. Clin Exp Immunol 1997; 107: 120-26.
40. Hashimoto H, Igarashi N, Yachie A, Miyawaki T, Hashimoto T, Sato T. The relationship between serum levels of interleukin-6 and thyroid hormone during the follow-up study in children with nonthyroidal illness: marked inverse correlation in Kawasaki and infectious disease. Endocr J 1996; 43: 31-38.
41. Hirao J, Hibi S, Audoh T, Ichimura T. High levels of circulating interleukin-4 and interleukin-10 in Kawasaki disease. Int Arch Allergy Immunol 1997; 112: 152-56.
42. Takeshita S, Dobashi H, Nakatani K et al. Circulating soluble selectins in Kawasaki disease. Clin Exp Immunol 1997; 108: 446-50.
43. Kim DS, Lee KY. Serum soluble E-selectin levels in Kawasaki Disease. Scand J Rheumtol 1994; 23: 283-86.
44. Irazuzta JE, Elbl F, Rees AR. Factor VIII related antigen (von Willebrand's Factor) in Kawasaki disease. Clin Pediatr 1990; 29: 347-48.
45. Mayatepek E, Lehmann WD. Increased generation of cysteinyl leukotrienes in Kawasaki Disease. Arch Dis Child 1995; 72: 526-27.
46. Matsubara T, Umezawa Y, Tsuru S, Motohashi T, Yabuta K, Furukawa S. Decrease in the concentrations of transforming growth factor-beta 1 in the sera of patients with Kawasaki disease. Scand J Rheum 1997; 26: 314-17.
47. Iizuka T, Oishi K, Sasaki M et al. Nitric oxide and aneurysm formation in Kawasaki disease. Acta Paediatr 1997; 86: 470-73.
48. Kuniyuki S, Asada M. An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. J Am Acad Dermatol 1997; 37: 303-304.
49. Nakamura Y, Yanagawa H, Kato H, Kawasaki T, and the Kawasaki Disease Follow-Up Group. Mortality rates for patients with a history of Kawasaki disease in Japan. J Pediatr 1996; 128: 75-81.
50. Fujiwara H, Hamashima Y. Pathology of the heart in Kawasaki disease. Pediatrics 1978; 61: 100-107.
51. Burns JC, Glode MP, Clarke SH, Wiggins J jr. Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of artery aneurysms. J Pediatr 1984; 105: 206-11.
52. Burns JC, Shike H, Gordon JB, Malhotra A, Schoenwetter M, Kawasaki T. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996; 28: 253-57.
53. Naoe S, Takahashi K, Masuda H, Tanaka N. Kawasaki disease with particular emphasis on arterial lesions. Acta Pathol Jpn 1991; 41: 785-97.
54. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974; 54: 271-76.
55. Morens DM, Anderson LJ, Hurwitz ES. National surveillance of Kawasaki disease. Pediatrics 1980; 65: 21-25.
56. Dajani AS, Taubert KA, Gerber MA et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993; 87: 1776-80.
57. Rauch AM. Kawasaki syndrome: critical review of U.S. epidemiology. Prog Clin Biol Res 1987; 250: 33-44.
58. Burns JC, Joffe L, Sargent RA, Glode MP. Anterior uveitis associated with Kawasaki syndrome. Pediatr Infect Dis 1985; 4: 258-61.
59. Burns JC, Mason WH, Glode MP et al for the United States Multicenter Kawasaki Disease Study Group. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. J Pediatr 1991; 118: 680-86.
60. Dengler LD, Capparelli EV, Bastian JF et al. Cerebrospinal fluid profile in patients with acute Kawasaki disease. J Ped Infect Dis J 1998; 17: 478-81.
61. Sty JR, Starshak RJ, Gorenstein L. Gallbladder perforation in a case of Kawasaki disease: image correlation. J Clin Ultrasound 1983; 11: 381-84.
62. Burns JC, Wiggins JW jr, Toews WH, Newburger JW, Wilson H, Glode MP. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr 1986; 109: 759-63.
63. Schuh S, Laxer RM, Smallhorn JF, Hilliard RI, Rowe RD. Kawasaki disease with atypical presentation. Pediatr Infect Dis J 1988; 7: 201-203.
64. Cloney DL, Teja K, Lohr JA. Fatal case of atypical Kawasaki syndrome. Pediatr Infect Dis J 1987; 6: 297-99.
65. Rowley AH, Gonzalez Crussi F, Gidding SS, Duffy CE, Shulman ST. Incomplete Kawasaki disease with coronary artery involvement. J Pediatr 1987; 110: 409-13.
66. Fukushige N, Takahashi N, Ueda K, Ueda Y. Incidence and clinical features of incomplete Kawasaki Disease. Acta Paediatr 1994; 83: 1057-60.
67. Gamillscheg A, Zobel G, Karpf EF et al. Atypical presentation of Kawasaki disease in an infant. Pediatr Cardiol 1993; 14: 223-26.
68. Joffe A. Atypical and complicated Kawasaki disease in infants. Do we need criteria? West J Med 1995; 162: 322-27.
69. Levy M, Koren G. Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. Pediatr Infect Dis J 1990; 9: 122-26.
70. von Planta M, Fasnacht M, Holm C, Fanconi S, Seger RA. Atypical Kawasaki disease with peripheral gangrene and myocardial infarction: therapeutic implications. Eur J Pediatr 1995; 154: 830-34.
71. Research Committee on Kawasaki Disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan: Ministry of Health and Welfare, 1984.
72. Asai T. Evaluation method for the degree of seriousness in Kawasaki disease. Acta Paediatr Jpn 1983; 25: 170-75.
73. Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease: review of risk factors for coronary aneurysms. J Pediatr 1986; 108: 388-92.
74. Ichida F, Fatica NS, Engle MA et al. Coronary artery involvement in Kawasaki syndrome in Manhattan, New York: risk factors and role of aspirin. Pediatrics 1987; 80: 828-35.
75. Daniels SR, Specker B, Capannari TE, Schwartz DC, Kaplan S. Correlates of coronary artery aneurysm formation in patients with Kawasaki disease. Am J Dis Child 1987; 141: 205-207.
76. Nakano M. Predictive factors of coronary aneurysm in Kawasaki disease-correlation between coronary arterial lesions and serum albumin, cholinesterase activity, prealbumin, retinol-binding protein and immature neutrophils. Prog Clin Biol Res 1987; 250: 535-37.
77. Newburger JW, Takahashi M, Burns JC et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315: 341-47.
78. Beiser AS, Takahasha M, Baker AL, Sundel RP, Newburger JW. for the United States Multicenter Kawasaki Disease Study Group. A predictive instrument for coronary artery aneurysms in Kawasaki disease. Am J Cardiol 1998; 81: 1116-20.
79. Yutani C, Okano K, Kamiya T et al. Histopathological study on right endomyocardial biopsy of Kawasaki disease. Br Heart J 1980; 43: 589-92.
80. Matsuura H, Ishikita T, Yamamoto S el al. Gallium-67 myocardial imaging for the detection of myocarditis. Br Heart J 1987; 58: 385-92.
81. Kao CH, Hsieh KS, Wang YL et al. Tc-99 m MHPAO WBC imaging to detect carditis and to evaluate the results of high-dose gamma globulin treatment in Kawasaki disease. Clin Nucl Med 1992; 17: 623-26.
82. Klassen TP, Rowe PC, Gafni A. Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome. J Pediatr 1993; 122: 538-42.
83. Kao CH, Hsieh K., Wang YL et al. Tc-99 m HMPAO labeled WBC scan for the detection of myocarditis in different phases of Kawasaki disease. Clin Nucl Med 1992; 17: 185-90.
84. Anderson TM, Meyer RA, Kaplan S. Long-term echocardiographic evaluation of cardiac size and function in patients with Kawasaki disease. Am Heart J 1985; 110: 107-15.
85. Hiraishi S, Yashiro K, Oguchi K, Kusano S, Ishii K, Nakazawa K. Clinical course of cardiovascular involvement in the mucocutaneous lymph node syndrome: relation between clinical signs of carditis and development of coronary arterial aneurysm. Am J Cardiol 1981; 47: 323-30.
86. Moran AM, Newburger JW, Sanders SP et al. Abnormal myocardial mechanics in Kawasaki syndrome: rapid response to gamma-globulin therapy Am Heart J 1999 (in press).
87. Tanaka N, Naoe S, Masuda H, Ueno T. Pathological study of sequelae of Kawasaki disease (MCLS). With special reference to the heart and coronary arterial lesions. Acta Pathol Jpn 1986; 36: 1513-27.
88. Takahashi M, Shimada H, Billingham ME, Mason W, Miller JH. Electron microscopic findings of myocardial biopsy correlated with perfusion scan and coronary angiography in chronic Kawasaki syndrome: myocellular ischemia possibly due to microvasculopathy. In: Kato H (ed). Kawasaki disease. Proceedings of the 5th International Kawasaki Disease Symposium, Fukuoka, Japan, 22-25 May 1995. Amsterdam: Elsevier Science BV, 1995; 401-10.
89. Chung KJ, Brandt L, Fulton DR, Kreidberg MB. Cardiac and coronary arterial involvement in infants and children from New England with mucocutancous lymph node syndrome (Kawasaki disease). Angiocardiographic-echocardiographic correlations. Am J Cardiol 1982; 50: 136-42.
90. Newburger JW, Sanders SP, Burns JC, Parness IA, Beiser AS, Colan SD. Left ventricular contractility and function in Kawasaki syndrome: effect of intravenous gamma globulin. Circulation 1989; 79: 1237-46.
91. Gidding SS. Late onset valvular dysfunction in Kawasaki disease. Prog Clin Biol Res 1987; 250: 305-309.
92. Kato H, Sugimura T, Akagi T et al. Long-term consequences of Kawasaki Disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996; 94: 1379-85.
93. Nakano H, Nojima K, Saito A, Ueda K. High incidence of aortic regurgitation following Kawasaki disease. J Pediatr 1985; 107: 59-63.
94. Gidding SS, Shulman ST, Ilbawi M, Crussi F, Duffy CE. Mucocutaneous lymph node syndrome (Kawasaki disease): delayed aortic and mitral insufficiency secondary to active valvulitis. J Am Coll Cardiol 1986; 7: 894-97.
95. Melish ME. Kawasaki syndrome: a 1986 perspective. Rheum Dis Clin North Am 1987; 13: 7-17.
96. Ting EC, Capparelli EV, Billman GF, Lavine JE, Matsubara T, Burns JC. Elevated gamma-glutamyltransterase concentrations in patients with acute Kawasaki disease. Pediatr Infect Dis J 1998; 17: 431-32.
97. Capannari TE, Daniels SR, Meyer RA, Schwanz DC. Sensitivity, specificity and predictive value of two-dimensional echocardiography in detecting coronary artery aneurysms in patients with Kawasaki disease. J Am Coll Cardiol 1986; 7: 355-60.
98. Sugimura T, Kato H, Inoue O, Takagi J, Fukuda T, Sato N. Vasodilatory response of the coronary arteries after Kawasaki disease: evaluation by intracoronary injection ofisosorbide dinitrate. J Pediatr 1992; 121: 684-88.
99. Oberhoffer R, Lang D, Feilen K. The diameter of coronary arteries in infants and children without heart disease. Eur J Pediatr 1989; 148: 389-92.
100. de Zorzi A, Colan SD, Gauvreau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998; 133: 254-58.
101. National Heart, Lung, and Blood Institute Coronary Artery Surgery Study. A multicenter comparison of the effects of randomized medical and surgical treatment of mildly symptomatic patients with coronary artery disease, and a registry of consecutive patients undergoing coronary angiography. Circulation 1981; 63 (suppl 1): 11-181.
102. Takahashi M, Mason W, Lewis AB. Regression of coronary aneurysms in patients with Kawasaki syndrome. Circulation 1987; 75: 387-94.
103. Kusakawa S, Tatara K. Efficacies and risks of aspirin in the treatment of the Kawasaki disease. Prog Clin Biol Res 1987; 250: 401-13.
104. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995; 96: 1057-61.
105. Koren G, Silverman E, Sundel R et al. Decreased protein binding of salicylates in Kawasaki disease. J Pediatr 1991; 118: 456-59.
106. Matsubara T, Mason W, Kashani IA, Kligerman M, Burns JC. Gastrointestinal hemorrhage complicating aspirin therapy in acute Kawasaki disease. J Pediatr 1996; 128: 701-703.
107. Takahashi M, Mason W, Thomas D, Sinatra F. Reye syndrome following Kawasaki syndrome confirmed by liver histopathology. In: Kato H (ed). Kawasaki disease. Proceedings of the 5th International Kawasaki Disease Symposium, Fukuoka, Japan, 22-25 May 1995. Amsterdam: Elsevier Science BV, 1995; 436-44.
108. Furusho K, Kamiya T, Nakano H et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; ii: 1055-58.
109. American Academy of Pediatrics. Committee on Infectious Diseases. Intravenous gamma-globulin use in children with Kawasaki disease. Pediatrics 1988; 82: 122.
110. Barron KS, Murphy DJ jr. Silverman ED et al. Treatment of Kawasaki syndrome: a comparison of two dosage regimens of intravenously administered immune globulin. J Pediatr 1990; 117: 638-44.
111. Engle MA, Fatica NS, Bussel JB, O'Loughlin JE, Snyder MS, Lesser ML. Clinical trial of single-dose intravenous gamma globulin in acute Kawasaki disease. Am J Dis Child 1989; 143: 1300-304.
112. Furusho K, Kamiya T, Nakano H et al. Japanese gamma globulin trials for Kawasaki disease. Prog Clin Biol Res 1987; 250: 425-32.
113. Morikawa Y, Ohashi Y, Harada K et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki Disease. Acta Paediatr Jpn 1994; 36: 347-54.
114. Murphy DJ jr, Huhta JC. Treatment of Kawasaki syndrome with intravenous gamma globulin [letter]. N Engl J Med 1987; 316: 881-88.
115. Nagashima M, Matsushima M, Matsuoka H, Ogawa A, Okumura N. High-dose gammaglobulin therapy for Kawasaki disease. J Pediatr 1987; 110: 710-12.
116. Okuni M, Harada K, Yamaguchi H, Yanagawa H, Sonobe T, Kawasaki T. Intravenous gamma globulin therapy in Kawasaki disease -trial. Prog Clin Biol Res 1987; 250: 433-39.
117. Rowley AH, Duffy CE, Shulman ST. Prevention of giant coronary artery aneurysms in Kawasaki disease by intravenous gamma globulin therapy. J Pediatr 1988; 113: 290-94.
118. Dajani AS, Taubert KA, Takahashi M et al. Guidelines for long-term management of patients with Kawasaki disease. Report from the Committee on Rheumatic Fever. Endocarditis, and Kawasaki Disease. Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994; 89: 916-22.
119. American Academy of Pediatrics. In: Peter G (ed). Kawasaki disease. Red Book: Report of the Committee on Infectious Diseases, 24th edition. Elk Grove Village, IL: American Academy of Pediatrics, 1997: 316-19.
120. Burns JC, Glode MP, Capparelli E, Brown JA, Newburger JW, for the US/Canadian Kawasaki Syndrome Study Group. Intravenous gammaglobulin treatment in Kawasaki syndrome: are all brands equal? In: Kato H (ed). Kawasaki disease. Proceedings of the 5th International Kawasaki Disease Symposium, Fukuoka, Japan, 22-25 May 1995. Amsterdam: Elsevier Science BV, 1995; 296-300.
121. Rosenfeld EA, Shulman ST, Corydon KE, Mason W, Takahashi M, Kuroda C. Comparative safety and efficacy of two immune globulin products in Kawasaki disease. In: Kato H (ed). Kawasaki disease. Proceedings of the 5th International Kawasaki Disease Symposium. Fukuoka, Japan, 22-25 May 1995. Amsterdam: Elsevier Science BV, 1995: 291-95.
122. Schneider LC, Geha R et al. Outbreak of hepatitis C associated with IVGG administration - US, October 1993 - June 1994. Morbidity and Mortality Weekly Report 1994; 43: 505-509.
123. Silverman ED, Huang C, Rose V et al. IVGG treatment of Kawasaki disease: are all brands equal? In: Kato H (ed). Kawasaki disease. Proceedings of the 5th International Kawasaki Disease Symposium, Fukuoka, Japan, 22-25 May 1995. Amsterdam: Elsevier Science BV, 1995: 301-304.
124. Harada K, Yamaguchi H, Kato H et al. Indication for intravenous gamma globulin treatment for Kawasaki disease. In: Takahasi M, Taubert K. Proceedings of the Fourth International Symposium on Kawasaki Disease, Dallas, TX: American Heart Association, 1993: 459-62.
125. Marasini M, Pongiglione G, Gazzolo D, Campelli A, Ribaldone D, Caponnetto S. Late intravenous gamma globulin treatment in infants and children with Kawasaki Disease and coronary artery abnormalities. Am J Cardiol 1991; 68: 796-97.
126. Newburger JW, Takahashi M, Beiser AS et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324: 1633-39.
127. Burns JC, Capparelli EV, Brown JA, Newburger JW. Intravenous gamma globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki Syndrome Study Group. Pediatr Inf Dis J 1998; 17: 1144-48.
128. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery. Pediatrics 1979; 63: 175-79.
129. Cremer H, Rieger C. Considerations on treatment in Kawasaki syndrome (KS). In: Program and Abstracts of the Third International Kawasaki Disease Symposium, Tokyo, Japan, 29 November-2 December 1988: 297-300.
130. Kifima Y, Kamiya T, Suzuki A, Hirose D, Manabe H. A trial procedure to prevent an aneurysm formation of the coronary arteries by steroid pulse therapy in Kawasaki disease. Jpn Circ 1982; 46: 1239-42.
131. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996; 128: 146-49.
132. Furukawa S, Matsubara T, Umezawa Y, Motohashi T , Ino T, Yabuta K. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. Eur J Pediatr 1994; 153: 663-67.
133. Villain E, Kachaner J, Sidi D, Blaysat G, Piechaud JF, Pedroni E. Trial of prevention of coronary aneurysms in Kawasaki's syndrome using plasma exchange of infusion of immunoglobulins [French]. Arch Fr Pediatr 1987; 44: 79-83.
134. Fujiwaia T, Fujiwara H, Hamashima Y. Size of coronary aneurysm as a determinant factor of the prognosis in Kawasaki disease: clinico-pathologic study of coronary aneurysms. Prog Clin Biol Res 1987; 250: 519-20.
135. Tatara K, Kusakawa S. Long-term prognosis of giant coronary aneurysm in Kawasaki disease: an angiographic study. J Pediatr 1987; 111: 705-10.
136. Nakano H, Saito A, Ueda K, Nojima K. Clinical characteristics of myocardial infarction following Kawasaki disease: report of 11 cases. J Pediatr 1986; 108: 198-203.
137. Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. N Engl J Med 1993; 329: 703-709.
138. Cheatham JP, Kugler JD, Gumhiner CH, Latson LA, Hofschire PJ. Intracoionary streptokinase in Kawasaki disease: acute and thrombolysis. Prog Clin Biol Res 1987; 250: 517-18.
139. Kishimo C, Takada H, Hiraoka Y, Kurokawa M, Ochiai H. Effects of levarnisole, an immunomodulator, upon murine encephalomyocarditis virus myocarditis. Heart Vessels 1997; 12: 67-73.
140. Levy M, Benson LN, Burrows PE. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr 1991; 118: 467-72.
141. Kato H, Ichinose E, Inoue O, Akagi T. Intracoronary thrombolytic therapy in Kawasaki disease: treatment and prevention of acute myocardial infarction. Prog Clin Biol Res 1987; 250: 445-54.
142. Burtt DM, Pollack P, Bianco JA. Intravenous streptokinase in an infant with Kawasaki's disease complicated by acute myocardial infarction. Pediatr Cardiol 1986; 6: 307-11.
143. Terai M, Ogata M, Sugimoto K et al. Coronary arterial thrombi in Kawasaki disease. J Pediatr 1985; 106: 76-78.
144. Shackelford PG, Strauss AW. Kawasaki syndrome: editorial. N Engl J Med 1991; 324: 1664-66.
145. Marder VJ, Sherry S. Thrombolytic therapy: current status (second of two parts). N Engl J Med 1988; 318: 1585-95.
146. Marder VJ, Sherry S. Thrombolytic therapy: current status (first of two parts). N Engl J Med 1988; 318: 1512-20.
147. Ino T, Iwahara M, Boku H et al. Aortocoronary bypass surgery for Kawasaki disease. Pediatr Cardiol 1987; 8: 195-97.
148. Nishida H, Endo M, Hayashi H, Koyanagi H, Takao A. Early occlusion of saphenous vein grafts due to marked intimal proliferation in Kawasaki disease. Prog Clin Biol Res 1987; 250: 527-28.
149. Kitamura S. Surgical treatment for coronary arterial lesions in Kawasaki disease. Prog Clin Biol Res 1987; 250: 455-58.
150. Hirose H, Kawashima Y, Nakano S et al. Long-term results in surgical treatment of children 4 years old or younger with coronary involvement due to Kawasaki disease. Circulation 1986; 74: 177-181.
151. Suzuki A, Kamiya T, Ono Y, Takahashi N, Naito Y, Kou Y, Indication of aortocoronary bypass for coronary arterial obstruction due to Kawasaki diseuse. Heart Vessels 1985; 1: 94-100.
152. Kitamura S, Kawachi K, Oyama C. Severe Kawasaki heart disease treated with an internal mammary artery graft in pediatric patients. A first successful report. J Thorac Cardiovasc Surg 1985; 89: 860-66.
153. Takeuchi Y, Suma K, Shiroma K, Asai T, Kusakawa S. Surgical experience with coronary arterial sequelae of Kawasaki disease in children. J Cardiovasc Surg 1981; 22: 231-38.
154. Kitamura S, Kameda Y, Seki T et al. Long-term outcome of myocardial revascularization in patients with Kawasaki coronary artery disease. J Thorac Cardiovasc Surg 1994; 107: 663-74.
155. Ino T, Akimoto K, Ohkubo M et al. Application of percutaneous transluminul coronary angioplasty to coronary arterial stenosis in Kawasaki disease. Circulation 1996; 93: 1709-15.
156. Sugimara T, Yokoi H, Sato N et al. Interventional treatment for children with severe coronary artery stenosis with calcification after long-term Kawasaki disease. Circulation 1997; 96: 3928-33.
157. Checchia PA, Pahl E, Shaddy RE, Shulman ST. Cardiac transplantation for Kawasaki disease. Pediatrics 1997; 100: 695-99.
158. Nakano H, Ueda K, Saito A, Nojima K. Repeated quantitative angiograms in coronary arterial aneurysm in Kawasaki disease. Am J Cardiol 1985; 56: 846-51.
159. Kamiya T, Suzuki A, Ono Y et al. Angiographic follow-up study of coronary artery lesion in the cases with a history of Kawasaki disease - with a focus on the follow-up more than ten years after the onset of the disease. Kawasaki Disease. In: Kato H (ed). Proceedings of the 5th International Kawasaki Disease Symposium, Fukuoka, Japan, 22-25 May 1995. The Netherlands: Elsevier Science BV, 1995; 569-73.
160. Fujiwara T, Fujiwara H, Hamashima Y. Frequency and size of coronary arterial aneurysm at necropsy in Kawasaki disease. Am J Cardiol 1987; 59: 808-11.
161. Tatara K, Kusakawa S. Long term prognosis of giant coronary aneurysms in Kawasaki disease. Prog Clin Biol Res 1987; 250: 579.
162. Suzuki A, Kamiya T, Arakaki Y, Kinoshita Y, Kimura K. Fate of coronary arterial aneurysms in Kawasaki Disease. Am J Cardiol 1994; 74: 822-24.
163. Rein AJJT, Colan SD, Parness IA, Sanders SP. Regional and global left ventricular function in infants with anomalous origin of the left coronary artery from the pulmonary trunk: preoperative and postoperative assessment. Circulation 1987; 75: 115-23.
164. Suzuki A, Kamiya T, Ono Y, Kohata T, Okuno M. Myocardial ischemia in Kawasaki disease: follow-up study by cardiac catheterization and coronary angiography. Pediatr Cardiol 1988; 9: 1-5.
165. Fukuda T, Akagi T, Ishibashi M, Inoue O, Sugimura T, Kato H. Noninvasive evaluation of myocardial ischemia in Kawasaki disease: comparison between dipyridamole stress thallium imaging and exercise stress testing. Am Heart J 1998; 135: 482-87.
166. Genma Y, Ogawa S, Zhang J, Yamamoto M. Evaluation of myocardial ischemia in Kawasaki disease by dobutamine stress signal-averaged ventricular late potentials. Cardiovasc Res 1997; 36: 323-29.
167. Karasawi K, Ayusawa M, Yamasita T et al. Pharmacologic stress myocardial perfusion imaging for the detection of coronary stenotic lesions due to Kawasaki disease: comparison of dobutamine and adenosine triphosphate disodium stress. Kawasaki Disease. In: Kato H (ed). Proceedings of the 5th International Kawasaki Disease Symposium, Fukuoka, Japan, 22-25 May 1995. The Netherlands: Elsevier Science BV, 1995; 466-71.
168. Kimball TR, Witt SA, Daniels SR. Dobutamine stress echocardiography in the assessment of suspected myocardial ischemia in children and young adults. Am J Cardiol 1997; 79: 380-84.
169. Noto N, Ayusawa M, Karasawa K, Yamaguchi H, Harada K. Combination of dobutamine stress and myocardial contrast echocardiography in Kawasaki Disease. Kawasaki Disease. In: Kato H (ed). Proceedings of the 5th International Kawasaki Disease Symposium, Fukuoka, Japan, 22-25 May 1995. The Netherlands: Elsevier Science BV, 1995; 460-65.
170. Noto N, Ayusawa M, Karasawa K et al. Dobutamine stress echocardiography for detection of coronary artery stenosis in children with Kawasaki disease. J Am Coll Cardiol 1996; 27: 1251-56.
171. Pahl E, Sehgal R, Chrystof D et al. Feasibility of exercise stress echocardiography for the follow-up of children with coronary involvement secondary to Kawasaki disease. Circulation 1995; 91: 122-28.
172. Hijazi ZM, Udelson JE, Snapper H et al. Physiologic significance of chronic coronary aneurysms in patients with Kawasaki disease. J Am Coll Cardiol 1994; 24: 1633-38.
173. Hamaoka K, Onouchi Z, Kamiya Y, Sakata K. Evaluation of coronary flow velocity dynamics and flow reserve in patients with Kawasaki disease by means of a Doppler guide wire. J Am Coll Cardiol 1998; 31: 833-40.
174. Sasaguri Y, Kato H. Regression of aneurysms in Kawasaki disease: a pathological study? J Pediatr 1982; 100: 225-31.
175. Fujiwara T, Fujiwara H, Nakano H. Pathological features of coronary arteries in children with Kawasaki Disease in which coronary arterial aneurysm was absent at autopsy. Circulation 1988; 78: 345-50.
176. Sugimura T, Kato H, Inoue O et al. Intravascular ultrasound of coronary arteries in children. Assessment of the wall morphology and the lumen after Kawasaki disease. Circulation 1994; 89: 258-65.
177. Kurisu Y, Azumi T, Sugahara T, Igarashi Y, Takainiya M. Variation in coronary arterial dimension (distensible abnormality) after disappearing aneurysm in Kawasaki disease. Am Heart J 1987; 114: 532-38.
178. Matsumura K, Okuda Y, Ito T, Hirano T, Takeda K. Coronary angiography of Kawasaki disease with the coronary vasodilator dipyridamole: assessment of distensibility of affected coronary arterial wall. Angiology 1988; 39: 141-47.
179. Spevak PJ, Newburger JW, Keane J, Selwyn A, Takahashi M. Reactivity of coronary arteries in Kawasaki syndrome: an analysis of function. Am J Cardiol 1987; 60: 640 [abstract].
180. Fulton DR, Meissner C, Peterson MB. Effects of current therapy of Kawasaki disease on eicosanoid metabolism. Am J Cardiol 1988; 61: 1323-27.
181. Newburger JW, Burns JC, Shen G, Brosius CL, Loscalzo J. Altered lipid metabolism following Kawasaki syndrome. Circulation 1987; 76: IV-515 [abstract].
182. Muzik O, Paridon SM, Singh TP, Morrow WR, Dayanikli F, DiCarli MF. Quantification of nivocardial blood flow and flow reserve in children with a history of Kawasaki disease and normal coronary arteries using positron emission tomography. J Am Coll Cardiol 1996; 28: 757-62.
183. Mitani Y, Okuda Y, Shimpo H et al. Impaired endothelial function in epicardial coronary arteries after Kawasaki disease. Circulation 1997; 96: 454-61.
184. Dhillon R, Clarkson P, Donald AE et al. Endothelial dysfunction late after Kawasaki disease. Circulation 1996; 94: 2103-106.
185. Paridon SM, Galioto FM, Vincent JA, Tomassoni TL, Sullivan NM, Bricker